Search Results

Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.

• Authors : Roskoski R Jr; Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address: .

Subjects: Protein Kinase Inhibitors*/therapeutic use

• Source: Pharmacological research [Pharmacol Res] 2024 Jan; Vol. 199, pp. 107036. Date of Electronic Publication: 2023 Dec 12.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium:

Record details

Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.

• Authors : Roskoski R Jr; Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791-8717, United States. Electronic address: .

Subjects: Neoplasms*/drug therapy

• Source: Pharmacological research [Pharmacol Res] 2023 Aug; Vol. 194, pp. 106847. Date of Electronic Publication: 2023 Jul 15.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8907422 Publication Model: Print-Electronic Cited Medium:

Record details

Shock over National Cancer Research Institute closure.

• Authors : Thornton J

Subjects: Shock* ;

Record details

Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020).

• Authors : Ribeiro TB; Department of Epidemiology. School of Public Health. University of Sao Paulo, São Paulo, Brazil. Electronic address: .

Subjects: Antineoplastic Agents*/therapeutic use

• Source: Journal of clinical epidemiology [J Clin Epidemiol] 2023 Jul; Vol. 159, pp. 151-158. Date of Electronic Publication: 2023 Apr 08.Publisher: Elsevier Country of Publication: United States NLM ID: 8801383 Publication Model:

Record details

Cardiovascular risk factor reporting in immune checkpoint inhibitor trials: A systematic review.

• Authors : Tan S; Victorian Heart Institute, Melbourne, Australia

Subjects: Cardiovascular Diseases*/epidemiology

• Source: Cancer epidemiology [Cancer Epidemiol] 2023 Apr; Vol. 83, pp. 102334. Date of Electronic Publication: 2023 Jan 18.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101508793 Publication Model: Print-Electronic Cited Medium:

Record details

Assessments of Somatic Variant Classification Using the Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists Guidelines: A Report from the Association for Molecular Pathology.

• Authors : Li MM; The Variant Interpretation Testing Across Laboratories (VITAL) Somatic Working Group of the Clinical Practice Committee, Association for Molecular Pathology, Rockville, Maryland

Subjects: Pathology, Molecular* ;

Record details

Advanced Dietary Analysis and Modeling: A Deep Dive into the National Cancer Institute Method.

• Authors : Luo H; Institute for Global Nutrition, University of California, Davis, CA, USA

Subjects: Neoplasms*;

Record details

Cancer-associated venous thromboembolism: Incidence and features in a racially diverse population.

• Authors : Raskob GE; Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

Subjects: Neoplasms*/complications

• Source: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2022 Oct; Vol. 20 (10), pp. 2366-2378. Date of Electronic Publication: 2022 Aug 07.Publisher: Elsevier Country of Publication: England NLM ID: 101170508 Publication Model: Print-Electronic Cited Medium:

Record details

Interventions to improve delivery of cancer genetics services in the United States: A scoping review.

• Authors : Bednar EM; Cancer Prevention and Control Platform, Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Subjects: Genetic Counseling* ;

Record details

External control arms in oncology: current use and future directions.

• Authors : Mishra-Kalyani PS; Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA. Electronic address: .

Subjects: Medical Oncology* ;

Record details